Novocure Ltd. Stock News

BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) will report financial results for the first quarter 2025 on April 24, 2025, before the U.S. financial markets open. Novocure management will host a conference call and webcast at 8:00 a.m. EDT, April 24, to discuss the company's financial results for the three-month quarter that ended March 31, 2025. To access the conference call by ph...

Explore the exciting world of NovoCure (NVCR -1.20%) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!

BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that management will participate in the Leerink Global Healthcare Conference on Tuesday, March 11, 2025. Christoph Brackmann, Chief Financial Officer, will take part in a fireside chat at 4:20 p.m. EST, as well as one-on-one meetings with investors throughout the event. A live audio webcast of this presentation can be a...

NovoCure remains a strong buy due to robust earnings, a growing core business, and a promising pipeline, particularly in lung and pancreatic cancer treatments. Q4 2024 earnings showed strong revenue growth despite an EPS miss driven by a stock-comp event related to FDA approval. Updated DCF analysis yields a $34 price target, with Wall Street consensus at $35.83, indicating significant upside p...

NovoCure's stock has risen 42% since my October recommendation, but revenue diversification outside of glioblastoma (GBM) remains a concern. Despite FDA approvals, TTFields therapy faces adoption challenges due to marginal survival benefits and high costs, impacting market growth. NovoCure's financial health shows sufficient liquidity short-term, but profit margins will compress and S&M costs w...

NovoCure Limited (NASDAQ:NVCR ) Q4 2024 Earnings Conference Call February 27, 2025 8:00 AM ET Company Participants Ingrid Goldberg - Investor Relations Bill Doyle - Chairman Ashley Cordova - Chief Executive Officer Christoph Brackmann - Chief Financial Officer Frank Leonard - Executive Vice President & President, NovoCure Oncology Nicolas Leupin - Chief Medical Officer Conference Call Participa...

Oncology treatment pioneer NovoCure (NVCR) reported mixed fourth-quarter 2024 earnings on Thursday, Feb. 27. Q4 revenue matched analysts' consensus expectations at $161.3 million and jumped 21% year over year.

BAAR, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update.